Verrica Pharmaceuticals Reports Strong 2025 Growth, Advances Pipeline
Event summary
- YCANTH net revenue grew 130% to $15.3 million in 2025, with selling, general and administrative expenses decreasing by over 40% compared to 2024.
- Total revenue for 2025 reached $35.6 million, up from $7.6 million in 2024.
- YCANTH dispensed applicator units grew 99% to 51,296 in 2025 versus 25,773 units in 2024.
- Company advanced VP-315 toward a Phase 3 program for basal cell carcinoma in 2026, with supportive data on abscopal effects and tumor size reduction.
- First patient dosed in the first Phase 3 study of YCANTH for common warts in December 2025, with the second Phase 3 study expected to initiate in mid-2026.
The big picture
Verrica Pharmaceuticals' strong financial performance in 2025, marked by significant revenue growth and cost reductions, positions the company for further expansion in the dermatology and oncology sectors. The advancement of YCANTH and VP-315 through clinical trials and regulatory pathways highlights Verrica's strategic focus on addressing unmet medical needs in skin diseases and skin cancers. The company's ability to secure non-dilutive funding and extend its cash runway into 2027 provides a solid foundation for future growth and innovation.
What we're watching
- Commercial Execution
- How Verrica will sustain the momentum in YCANTH sales and expand its market reach, particularly with the upcoming Phase 3 studies for common warts.
- Pipeline Progress
- Whether VP-315 can successfully navigate the Phase 3 program for basal cell carcinoma and demonstrate the potential abscopal effects in clinical trials.
- Regulatory Strategy
- The pace at which Verrica can secure regulatory approvals for YCANTH in the European Union and other international markets, leveraging the positive feedback from the European Medicines Agency.
Related topics